Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Journal: Cancer biology & therapy
Published: February 07, 2018
PDE5 inhibitors enhance celecoxib killing in multiple tumor types.
Journal: Journal of cellular physiology
Published: September 15, 2014
Showing 1-2 of 2
Last Updated: 09/26/2026